Participant characteristics and buprenorphine dose

American Journal of Drug and Alcohol Abuse

Volumn 37, Issue 5, 2011, Pages 453-459

  Hillhouse, Maureen ^a   Canamar, Catherine P ^a   Doraimani, Geetha ^a   Thomas, Christie ^a   Hasson, Albert ^a   Ling, Walter ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Buprenorphine; Dose; Opioids; Treatment

Indexed keywords

BUPRENORPHINE PLUS NALOXONE;

ADULT; ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; DEMOGRAPHY; DRUG DOSE COMPARISON; FEMALE; HEALTH EDUCATION; HEROIN DEPENDENCE; HUMAN; MAINTENANCE THERAPY; MALE; OPIATE ADDICTION; WITHDRAWAL SYNDROME;

ADULT; ANALGESICS, OPIOID; BUPRENORPHINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEROIN DEPENDENCE; HUMANS; MALE; MIDDLE AGED; NALOXONE; NARCOTIC ANTAGONISTS; NATIONAL INSTITUTE ON DRUG ABUSE (U.S.); OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; UNITED STATES;

EID: 80052190205     PISSN: 00952990     EISSN: 10979891     Source Type: Journal    
DOI: 10.3109/00952990.2011.596974     Document Type: Article

References (27)

1. Amass L, Kamien JB, Mikulich SK. Efficacy of daily and alternate-day dosing regimens with the combination buprenorphine-naloxone tablet. Drug Alcohol Depend 2000; 58:143-152.
2. Copenhaver MM, Bruce RD, Altice FL. Behavioral counseling content for optimizing the use of buprenorphine for treatment of opioid dependence in community-based settings: A review of the empirical evidence. Am J Drug Alcohol Abuse 2007; 33:643-654. (Pubitemid 47463773)
3. Fiellin DA, Rosenheck RA, Kosten TR. Office-based treatment for opioid dependence: Reaching new patient populations. Am J Psychiatry 2001; 158:1200-1204. (Pubitemid 32717691)
4. Fudala PF, Yu E, MacFadden W, Boardman C, Chiang CN. Effects of buprenorphine and naloxone in morphine-stabilized opioid addicts. Drug Alcohol Depend 1998; 50:1-8. (Pubitemid 28176605)
5. Ling W, Charuvastra C, Collins JF, Batki S, Brown LS, Jr, Kintaudi P, Wesson DR, McNicholas L, Tusel DJ, Malkerneker U, Renner JA, Jr, Santos E, Casadonte P, Fye C, Stine S,Wang RIH, Segal D. Buprenorphine maintenance treatment of opiate dependence: A multicenter randomized clinical trial. Addiction 1998; 93:475-486. (Pubitemid 28188067)
6. Ling W, Wesson DR, Charuvastra C, Klett J. A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Arch Gen Psychiatry 1996; 53:401-407. (Pubitemid 26149228)
7. Ling W, Wesson DR. Clinical efficacy of buprenorphine: Comparisons to methadone and placebo. Drug Alcohol Depend 2003; 70:S49-57. (Pubitemid 36556060)
8. Ling W, Amass L, Shoptaw S, Annon J, Hillhouse M, Babcock D, et al. A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: Findings from the National Institute on Drug Abuse Clinical Trials Network. Addiction 2005; 100:1090-1100. (Pubitemid 41113602)
9. Ling W, Hillhouse M, Domier C, Doraimani G, Hunter J, Thomas C, Jenkins J, Hasson A, Annon J, Saxon A, Selzer J, Boverman J, Bilangi R. Buprenorphine tapering schedule and illicit opioid use. Addiction 2009; 104:256-265.
10. Fischer G, Gombas W, Eder H, Jagsch R, Peternell A, Stuhlinger G, Pezawas L, Aschauer HN, Kasper S. Buprenorphine versus methadone maintenance for the treatment of opioid dependence. Addiction 1999; 94:1337-1347. (Pubitemid 29433792)
11. Kosten TR, Schottenfeld R, Ziedonis D, Falcioni J. Buprenorphine versus methadone maintenance for opioid dependence. J Nerv Ment Dis 1993; 181:358-364. (Pubitemid 24259606)
12. Mattick RP, Ali R, White JM, OBrien S, Wolk S, Danz C. Buprenorphine versus methadone maintenance therapy: A randomized double-blind trial with 405 opioid-dependent patients. Addiction 2003; 98:441-452. (Pubitemid 36458126)
13. Petitjan S, Stohler R, Deglon JJ, Livoti S, Waldvogel D, Uehlinger C, Ladewig D. Double-blind randomized trial of buprenorphine and methadone in opiate dependence. Drug Alcohol Depend 2001; 62:97-104. (Pubitemid 32149970)
14. Schottenfeld RS, Pakes JR, Oliveto A, Ziedonis D, Kosten TR. Buprenorphine vs. methadone maintenance treatment for concurrent opioid dependence and cocaine abuse. Arch Gen Psychiatry 1997; 54:713-720. (Pubitemid 27344098)
15. Barnett PG, Rodgers JH, Bloch DA. A meta-analysis comparing buprenophine to methadone for treatment of opiate dependence. Addiction 2001; 96:683-690. (Pubitemid 32458706)
16. Gerra G, Borella F, Zaimovic A, Moi G, Bussandri M, Bubici C, Bertacca S. Buprenorphine versus methadone for opioid dependence: Predictor variables for treatment outcome. Drug Alcohol Depend 2004; 75:37-45. (Pubitemid 38844575)
17. Ling W, Smith D. Buprenorphine: Blending practice and research. J Subst Abuse Treat 2002; 23:87-92. (Pubitemid 36151691)
18. Chiang CN, Hawks R. Development of a buprenorphinenaloxone combination drug for the treatment of drug addiction. In Problems of Drug Dependence 1993, NIDA Research Monograph No. 141. Harris LS, ed. Washington, DC: US Government Printing Office, 1994; 458.
19. Jones HE. Practical considerations for the clinical use of buprenorphine. Sci Pract Perspect 2004; August:4-19.
20. Compton PA, Wesson DR, Charuvastra VC, Ling W. Buprenorphine as a pharmacotherapy for opiate addiction. Am J Addict 1996; 5:220-230.
21. McLellan AT, Kushner H, Metzger D, Peters R, Smith I, Grissom G, et al. The fifth edition of the addiction severity index. J Subst Abuse Treat 1992; 9:199-213.
22. Wesson DR, Ling W. Clinical opiate withdrawal scale (COWS). J Psychoactive Drugs 2003; 35:253-259. (Pubitemid 36927370)
23. Bickel WK, Stitzer MI, Bigelow GE, Liebson IA, Jasinski DR, Johnson RE. A clinical trial of buprenorphine: Comparison with methadone in the detoxification of heroin addicts. Clin Pharmacol Ther 1988; 43:72-78. (Pubitemid 18052024)
24. Bickel WK, Stitzer MI, Bigelow GE, Liebson IA, Jasinski DR, Johnson RE. Buprenorphine: Dose-related blockade of opioid challenge effects in opioid dependent humans. J Pharmacol Exp Ther 1988; 247:47-53.
25. Ling W, Shoptaw S, Wesson D, Rawson RA, Compton M, Klett CJ. Treatment effectiveness score as an outcome measure in clinical trials. NIDA Res Monogr 1997; 175:208-220. PMID: 9467800.
26. Ling W, Hillhouse M, Domier C, Doraimani G, Hunter J, Thomas C, Jenkins J, Hasson A, Annon J, Saxon A, Selzer J, Boverman J, Bilangi R. Long suffering or prolonged suffering? Time matters. Addiction 2009; 104: 1429-1430.
27. McCance-Katz E. Office-based buprenorphine treatment for opioid-dependent patients. Harv Rev Psychiatry 2004; 12:321-338. (Pubitemid 40144219)